Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio Holdings Inc (TVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,641
  • Shares Outstanding, K 198,690
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,730 K
  • EBIT $ -31 M
  • EBITDA $ -30 M
  • 60-Month Beta -0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.03 on 11/14/25
  • Next Earnings Date 04/01/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3400 +0.68%
on 12/29/25
0.4664 -26.61%
on 12/09/25
-0.0989 (-22.42%)
since 11/28/25
3-Month
0.3400 +0.68%
on 12/29/25
0.8090 -57.69%
on 09/30/25
-0.4453 (-56.54%)
since 09/29/25
52-Week
0.3400 +0.68%
on 12/29/25
1.9200 -82.17%
on 01/27/25
-0.6877 (-66.77%)
since 12/27/24

Most Recent Stories

More News
Tevogen CEO Donates Shares to Support Education for Underprivileged Children

WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen CEO Donates Personal Shares to Support Local Fire Department

WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock

WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that it has been named to the 2025 New Jersey Power List...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

This milestone expands patient eligibility through multi-HLA targeting Builds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patients...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today issued a statement to provide clarity regarding its accumulated deficit...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), in ongoing community, industry, and academic engagements, has continued...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records. Potential future T cell therapies could reliably bind to their target nearly every...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today highlights emerging scientific evidence linking persistent viral...

TVGNW : 0.0406 (-8.14%)
TVGN : 0.3471 (-8.83%)

Business Summary

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Tevogen Bio Holdings Inc., formerly known as SEMPER PAR ACQ, is based in Warren, New Jersey.

See More

Key Turning Points

3rd Resistance Point 0.4127
2nd Resistance Point 0.4054
1st Resistance Point 0.3930
Last Price 0.3471
1st Support Level 0.3733
2nd Support Level 0.3660
3rd Support Level 0.3536

See More

52-Week High 1.9200
Fibonacci 61.8% 1.3164
Fibonacci 50% 1.1300
Fibonacci 38.2% 0.9436
Last Price 0.3471
52-Week Low 0.3400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar